News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,599 Results
Type
Article (14254)
Company Profile (281)
Press Release (253064)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79547)
Career Advice (157)
Deals (13229)
Drug Delivery (35)
Drug Development (50461)
Employer Resources (31)
FDA (5722)
Job Trends (5136)
News (144457)
Policy (10033)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21672)
ALS (63)
Alzheimer's disease (844)
Antibody-drug conjugate (ADC) (94)
Approvals (5745)
Artificial intelligence (120)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (42)
Biotechnology (232)
Bladder cancer (49)
Brain cancer (20)
Breast cancer (149)
Cancer (1396)
Cardiovascular disease (116)
Career advice (137)
Career pathing (2)
CAR-T (112)
Cell therapy (317)
Cervical cancer (8)
Clinical research (41024)
Collaboration (529)
Compensation (256)
Complete response letters (13)
COVID-19 (1034)
CRISPR (39)
C-suite (157)
Cystic fibrosis (76)
Data (1440)
Denatured (11)
Depression (29)
Diabetes (133)
Diagnostics (1295)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (83)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (88)
Earnings (29763)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48378)
Executive appointments (449)
FDA (6396)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (488)
Gene editing (93)
Generative AI (10)
Gene therapy (241)
GLP-1 (364)
Government (1078)
Grass and pollen (2)
Guidances (19)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (89)
Indications (19)
Infectious disease (1099)
Inflammatory bowel disease (111)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (64)
Interviews (17)
IPO (7270)
IRA (11)
Job creations (864)
Job search strategy (131)
Kidney cancer (6)
Labor market (5)
Layoffs (206)
Leadership (3)
Legal (1387)
Liver cancer (31)
Lung cancer (197)
Lymphoma (94)
Machine learning (2)
Management (7)
Manufacturing (133)
MASH (50)
Medical device (2596)
Medtech (2597)
Mergers & acquisitions (6280)
Metabolic disorders (380)
Multiple sclerosis (52)
NASH (13)
Neurodegenerative disease (63)
Neuropsychiatric disorders (25)
Neuroscience (1239)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1646)
Now hiring (22)
Obesity (192)
Opinion (102)
Ovarian cancer (61)
Pain (41)
Pancreatic cancer (53)
Parkinson's disease (119)
Partnered (8)
Patents (125)
Patient recruitment (73)
Peanut (35)
People (25623)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14487)
Phase II (19082)
Phase III (12068)
Pipeline (776)
Policy (44)
Postmarket research (852)
Preclinical (6085)
Press Release (30)
Prostate cancer (59)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (286)
Real estate (1418)
Recruiting (12)
Regulatory (8610)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (58)
Series A (96)
Series B (60)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1442)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1972)
State (1)
Stomach cancer (4)
Supply chain (22)
Tariffs (6)
The Weekly (36)
United States (12842)
Vaccines (208)
Venture capitalists (31)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Today (105)
Last 7 days (297)
Last 30 days (1461)
Last 365 days (19560)
2025 (5709)
2024 (20551)
2023 (22415)
2022 (26822)
2021 (27809)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11845)
2015 (14360)
2014 (10393)
2013 (7489)
2012 (7533)
2011 (7617)
2010 (7433)
Location
Africa (148)
Alabama (41)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17277)
Australia (2931)
California (3733)
Canada (1111)
China (342)
Colorado (145)
Connecticut (149)
Delaware (95)
Europe (37164)
Florida (450)
Georgia (115)
Idaho (16)
Illinois (226)
India (10)
Indiana (91)
Iowa (1)
Japan (73)
Kansas (61)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (464)
Massachusetts (2958)
Michigan (70)
Minnesota (144)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (938)
New Mexico (12)
New York (1012)
North Carolina (540)
North Dakota (4)
Northern California (1646)
Ohio (111)
Oklahoma (9)
Oregon (21)
Pennsylvania (708)
Puerto Rico (5)
Rhode Island (18)
South America (208)
South Carolina (4)
Southern California (1442)
Tennessee (25)
Texas (434)
Utah (50)
Virginia (76)
Washington D.C. (30)
Washington State (343)
Wisconsin (14)
267,599 Results for "sangamo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in preclinical studies has shown the ability to cross the blood-brain barrier.
April 4, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Press Releases
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
April 4, 2025
·
5 min read
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
March 17, 2025
·
19 min read
Press Releases
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
March 6, 2025
·
2 min read
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
·
3 min read
·
Tyler Patchen
Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc., a genomic medicines company, reported business highlights and first quarter 2024 financial results.
May 9, 2024
·
17 min read
Press Releases
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
December 19, 2024
·
7 min read
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
December 19, 2024
·
7 min read
1 of 26,760
Next
